Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?

Key Takeaways Novo Nordisk shares gained 10% in a month on positive study data and restructuring news.The company plans to cut 9,000 jobs to save DKK 8B annually and refocus on diabetes and obesity.Earnings cuts, Wegovy's slower uptake, and rivalry from Eli Lilly's drugs cloud NVO's near-term outlook.Novo Nordisk (NVO) shares have climbed 10% in the past month, supported by a mix of certain internal factors and positive market catalysts, which boosted investor confidence.In early September, Novo Nordisk rep ...